Lazcluze Shows Central Nervous System Activity In EGFR-Variant NSCLC
Lazcluze shows promise as a potential treatment option for patients with EGFR-variant NSCLC, demonstrating significant central nervous system activity in ...
Tag: Non-small cell lung cancer (NSCLC)
Perioperative Opdivo Extends Event-Free Survival in Lung Cancer
Patients with resectable (surgically unremovable) non-small cell lung cancer (NSCLC) undergoing treatment with perioperative Opdivo (nivolumab) demonstrated extended event-free survival ...
Oncology Drugs Approved by the FDA in September 2024
List of oncology drugs approved by the FDA in September 2024.Throughout the month of September, several cancer therapies were approved ...
Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC
Patients with stage 4 non-small cell lung cancer (NSCLC) treated with either a standard or reduced dose of Keytruda (pembrolizumab) ...
Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC
Among patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), treatment via Krazati (adagrasib) was associated with superior outcomes when ...
Navigating the Cancer Journey With Two Different Approaches
From my lung cancer diagnosis in the summer of 2018 through treatment, remission and now a couple of years into ...
Rybrevant Plus Chemo Results in Superior Outcomes in EGFR-Mutant Advanced NSCLC
A new study finds that the combination of Rybrevant and chemotherapy improves overall survival in patients with EGFR-mutant advanced non-small ...